Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling-Reference-Cited by-同舟云学术

Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling

Published:2017-03 Issue: Volume:6 Page:89-105
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Moisan Annie,Gubler Marcel,Zhang Jitao David,Tessier Yann,Dumong Erichsen Kamille,Sewing Sabine,Gérard Régine,Avignon Blandine,Huber Sylwia,Benmansour Fethallah,Chen Xing,Villaseñor Roberto,Braendli-Baiocco Annamaria,Festag Matthias,Maunz Andreas,Singer Thomas,Schuler Franz,Roth Adrian B.

Funder

Roche Postdoctoral Fellowship

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference32 articles.

1. Designing chemically modified oligonucleotides for targeted gene silencing;Deleavey;Chem. Biol.,2012

2. Toxicologic properties of phosphorothioate 2′−O-methoxyethyl chimeric antisense inhibitors in animals and man;Henry,2007

3. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study;Voit;Lancet Neurol.,2014

4. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma;Herrington;Am. J. Kidney Dis.,2011

5. Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey;Henry;Toxicology,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the Inhibition of Organic Anion Transporter on Tricyclo-DNA-Mediated Exon Skipping in the mdx Mouse Model;Nucleic Acid Therapeutics;2023-12-01

2. P02-02: Evaluation of urinary safety biomarker panel to improve monitoring of preclinical Antisense Oligonucleotide-induced tubular kidney toxicity;Toxicology Letters;2023-09

3. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides;Nucleic Acid Therapeutics;2023-02-01

4. Antisense oligonucleotide is a promising intervention for liver diseases;Frontiers in Pharmacology;2022-12-09

5. Nephrotoxicity of marketed antisense oligonucleotide drugs;Current Opinion in Toxicology;2022-12